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ABSTRACT 
Objective: The objective of this selective EBM review is to determine whether or not propranolol 
administration following a traumatic event is effective in reducing symptoms of post-traumatic 
stress disorder (PTSD). 
Study Design: Review of three English language randomized, double-blind, placebo-controlled 
clinical trials published in 2002, 2007, and 2010. 
Data Sources: Three randomized, double-blind, placebo-controlled clinical trials found using 
PubMed and Cochrane Library databases.  
Outcome(s) Measured: The incidence of PTSD symptoms was measured in patients following 
traumatic events after the administration of propranolol. This was done using The Screening 
Tool for Early Predictors of PTSD, the Clinician Administered PTSD Scale for Children and 
Adolescents, the Clinician Administered PTSD Scale (CAPS), Script-driven Imagery, The Acute 
Stress Disorder Scale, the CIDI Modules for PTSD, MDD, and panic disorder, the DSM-IV, and 
The Posttraumatic Stress Disorder Checklist.  
Results: Three randomized, double-blind, placebo-controlled studies comparing propranolol to 
placebo were reviewed. The Nugent study demonstrated a clinical benefit of propranolol vs. 
placebo in PTSD symptoms in a pediatric sample. The Pitman study showed inconclusive results 
for using propranolol over placebo in incidence of PTSD symptoms in an adult sample. The 
Stein study did not show a difference in incidence of PTSD symptoms in propranolol vs. placebo 
in an adult sample.  
Conclusion: While it remains inconclusive at this time as to the benefit of propranolol in 
reducing PTSD symptoms, two of the trials support the clinical feasibility of this hypothesis. 
Further studies are warranted to investigate the relationship between propranolol administration 
and the development of PTSD symptomatology. 
Key Words: Propranolol, Post-Traumatic Stress Disorder 
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INTRODUCTION 
 Post-traumatic stress disorder (PTSD) is defined as a pathological anxiety that usually 
occurs after an individual experiences or witnesses severe trauma that constitutes a threat to the 
physical integrity or life of the individual or another person1. PTSD affects 7.7 million 
Americans annually, and the current lifetime prevalence is estimated to be 6.8%1, 2. 
 While it is difficult to calculate the total amount of health care dollars spent on PTSD in 
the United States every year, it is thought that the annual cost to society of anxiety disorders 
exceeds 42 billion dollars per year2. Cost continues to be a major issue in PTSD treatment, 
especially for veterans. During fiscal years 2004-2009, the Veterans Health Administration spent 
60% of its funding on patients with PTSD, Traumatic Brain Injury (TBI), or both, totaling 2.2 
billion dollars3. It is thought that the number of patients suffering from PTSD is thought to be 
much higher than the number of individuals seeking help. And while the exact number of annual 
health care visits for PTSD remains unknown, it is estimated that between 5 and 7 million 
Americans seek help for PTSD each year1,2,3.  
 There is no one cause for PTSD, but the condition is believed to be caused by a 
combination of a wide range of traumatic events, genetics, coping styles, lack of social support, 
and neurobiology. The disorder is characterized by disturbing recurrent flashbacks, avoidance of 
memories of the event, and hyper-arousal2. Studies have found that combat experience, 
childhood trauma, chronic adversity, familial stressors, drug misuse, and an upbringing in foster 
care put individuals at an increased risk for PTSD2. It appears that PTSD shares many of the 
same genetic influences with other psychiatric disorders. Studies have shown that panic, 
generalized anxiety disorders, and PTSD share 60% of the same genetic variance4. 
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 Usual methods for treating PTSD may include Cognitive Behavioral Therapy (CBT), 
Exposure Therapy, and Eye Movement Desensitization and Reprocessing1, 2. Medications 
constitute a large role in the treatment of PTSD, and medications used include SSRIs (ex. 
sertraline, fluoxetine), benzodiazepines (ex. lorazepam, diazepam), and anticonvulsants and 
mood stabilizers (ex. carbamazepine, topiramate, lamotrigine) 1, 2. Current treatments of PTSD 
focus on managing the signs and symptoms of the condition through various therapies and 
medications, yet little research has been done on strategies to prevent the development of PTSD 
following a traumatic event. One such drug hypothesized to prevent the development of PTSD 
symptoms is the non-selective beta-blocker propranolol, a drug whose action works through 
inhibiting the body’s response to sympathetic nerve impulses. Due to propranolol’s effect on 
beta-adrenergic receptors, it is theorized that propranolol administration following a traumatic 
event may inhibit the formation of traumatic memories by preventing stimulation of 
norepinephrine on the amygdala5, 6, 7. 
OBJECTIVE 
 The objective of this systematic review is to determine whether or not propranolol 
administration following a traumatic event is effective in reducing symptoms of PTSD.  
METHODS 
 Three randomized, double-blind, controlled clinical trials were utilized in this review. 
Interventions included propranolol administration at various doses following an acutely 
traumatic event in populations deemed at risk for PTSD; these populations included pediatric 
injury patients, patients following an acutely traumatic event, and surgical trauma center patients. 
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Comparisons were made to administration of placebo, and in one study, administration of 
gabapentin. Outcomes measured were incidence of PTSD symptoms in the selected populations.  
 Key words used in the search consisted of “propranolol”, “post-traumatic stress 
disorder”, and “PTSD”. All articles were published in English and in peer reviewed journals. The 
author undertook the search for articles using Medline and Pubmed, and articles were selected 
based on their relevance to the clinical question as well as inclusion of patient oriented evidence 
that matters (POEMs). Inclusion criteria consisted of articles utilizing randomized, controlled, 
double blind trials. Exclusion criteria consisted of studies published before 1996 or studies using 
disease-oriented outcomes (DOE). The statistics used and reported in the studies include control 
event rate (CER), experimental event rate (EER), absolute risk reduction (ARR), and number 
needed to treat (NNT). Demographics and characteristics of the studies are shown in Table 1.  
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Table 1: Demographics and Characteristics of included studies 
Study Type # Pts Age 
(yrs) 
Inclusion 
Criteria 
Exclusion 
Criteria 
W/
D 
Intervention 
Nugent5 
(2010) 
RCT 29 10-18  age 10-18 at risk 
for PTSD within 
12 hours of 
admission; GCS 
score > 14 
hypersensitivity 
to beta-blockers, 
bradycardia, 
cardiogenic or 
hypovolemic 
shock, diabetes, 
preexisting heart 
condition, 
treatment for 
asthma, or if 
injuries or 
medical treatment 
contraindicated 
propranolol 
0 oral solution 
of 
propranolol 
(HCL 20 
mg/5 ml) 
b.i.d. for 10 
days 
Pitman6 
(2002) 
RCT 41 n/a Emergency 
Department 
patients who had 
just experienced 
a traumatic 
event 
serious physical 
injury, substance 
intoxication, 
pregnancy, or 
lifetime history 
of congestive 
heart failure, 
heart block, or 
asthma, HR < 80 
bpm, systolic BP 
< 100 mm Hg 
10 40 mg oral 
propranolol 
4x daily for 
3 months 
Stein7 
(2007) 
RCT 48 18-65 Pts admitted to 
the University of 
California Level 
1 Surgical 
Trauma Center 
Lived too far for 
home monitoring, 
medically 
unstable, not 
English speaking, 
age . 65 or < 18, 
suicidal, 
homeless, jail or 
police hold, 
cardiac or seizure 
medications, 
active military 
10 Propranolol 
started at 20 
mg t.i.d. and 
uptitrated 
over 2 days 
to 40 mg 
t.i.d. x 8 
days, 
followed by 
taper x 4 
days. 
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OUTCOMES MEASURED 
The incidence of PTSD symptoms was measured in patients following traumatic events 
after the administration of propranolol. This was done using The Screening Tool for Early 
Predictors of PTSD, the Clinician Administered PTSD Scale for Children and Adolescents, the 
Clinician Administered PTSD Scale (CAPS), Script-driven Imagery, The Acute Stress Disorder 
Scale, the CIDI Modules for PTSD, MDD, and panic disorder, the DSM-IV, and The 
Posttraumatic Stress Disorder Checklist. 
RESULTS 
 The three double-blind, randomized clinical trials in this systematic review compared the 
effect of propranolol administration vs. administration of placebo in reducing incidence of PTSD 
symptomatology following a traumatic event. All three studies use dichotomous data. 
 In the Nugent study, 29 pediatric injury patients between the ages of 10-18 at risk for 
PTSD were randomized to a double blind 10 day trial of propranolol vs. placebo. The 
propranolol and placebo were administered to the patients within 12 hours of their admission to 
the emergency department and PTSD symptoms were assessed after 6 weeks. Eligibility criteria 
included an “at risk” for PTSD using The Screening Tool for Early Predictors of PTSD and a 
Glasgow Coma Scale score of 14 or greater. The subjects were administered an oral solution of 
propranolol (HCL 20 mg/5 ml) or liquid placebo twice daily for 10 days. An in-home follow-up 
assessment was undertaken 6 weeks post-trauma where the children were asked to give a 5 
minute narrative of their trauma followed by administration of the Clinician Administered PTSD 
Scale for Children and Adolescents (CAPS-CA). Results are seen below in Tables 2, 3, and 4. 
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 Table 2: Efficacy of Propranolol vs. Placebo in the Nugent et al. Study 
 All subjects (n = 26) Propranolol (+/- SD) Placebo (+/- SD) 
Mean CAPS-CA 
Score at 6 weeks post-
trauma 
24.4 (+/- 19.0) 27.8 (+/- 24.1) 21.6 (+/- 13.8) 
 
Table 3: PTSD Rates in Nugent et al. Study, 6 Week Follow-Up 
 Propranolol (n=12) Placebo (n=14) 
Number of patients meeting at 
least partial PTSD criteria 6 
weeks post-trauma 
42% 58% 
 
Table 4: Absolute Risk Reduction and Number Needed to Treat Nugent et al. Study, 6 
Week Follow-Up 
CER EER ARR NNT 
58% 42% 16% 1/16% = 7 
 
 The Pitman study randomized 41 emergency department patients who had just 
experienced a traumatic event that met the DSM-IV PTSD A.1 (stressor) and A.2 (response) 
criteria. Subjects were randomized to receive either 40 mg of propranolol or placebo as soon as 
possible after the event and no longer than 6 hours after the traumatic event. Upon discharge 
from the emergency department, the patients were instructed to continue the medication four 
times daily as tolerated for 10 days. This was then to be followed by a 9 day taper period. One 
and three months later, the subjects were asked to return to be administered the Clinician-
Administered PTSD Scale (CAPS) by a highly trained psychologist. Results are shown below in 
Tables 5, 6, 7, and 8. 
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Table 5: Efficacy of Propranolol vs. Placebo in the Pitman et al. Study, 1 Month Follow-Up 
 Propranolol (+/- SD) Placebo (+/- SD) 
Mean CAPS Score 27.6 (+/- 15.7) 35.5 (+/- 21.5) 
PTSD Rate 18% 30% 
 
Table 6: Absolute Risk Reduction and Number Needed to Treat Pitman et al. Study, 1 
Month Follow-Up 
CER EER ARR NNT 
30% 18% 12% 1/12% = 9 
 
Table 7: Efficacy of Propranolol vs. Placebo in the Pitman et al. Study, 3 Month Follow-Up 
 Propranolol (+/- SD) Placebo (+/- SD) 
Mean CAPS Score 21.1 (+/- 12.5) 20.5 (+/- 21.7) 
PTSD Rate 11% 13% 
 
Table 8: Absolute Risk Reduction and Number Needed to Treat in Pitman et al. Study, 3 
Month Follow-Up 
CER EER ARR NNT 
13% 11% 2% 1/2% = 50 
 
 In the Stein study, men and women ages 18-65 admitted to the University of California 
San Diego Level 1 Surgical Trauma Center during a 39 month period between 2001-2004 were 
recruited to participate in the study. 48 patients volunteered to participate and were randomized 
to receive either propranolol (n=17), gabapentin (n=14), or placebo (n=17). Medication was 
administered to subjects within 48 hours of admittance to the trauma center, and once started, 
subjects were asked to continue the medication for 14 days. Propranolol was started at 20 mg for 
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3 times daily and uptitrated over 2 days to 40 mg 3 times daily. Gabapentin was started at 300 
mg 3 times daily and uptitrated over 2 days to 400 mg 3 times daily. Assessments were 
conducted by telephone at 1, 4, and 8 months post-injury. The assessments included the Acute 
Stress Disorder Scale (1 month), the Comprehensive International Diagnostic Interview modules 
for PTSD, MDD, and Panic Disorder (4 and 8 months), the Center for Epidemiologic Studies 
Depression Scale (1, 4, and 8 months), and, principally, the Posttraumatic Stress Disorder 
Checklist-Civilian Version (1, 4, and 8 months). The DSM-IV was used to calculate PTSD rates 
at 4 months. Results are shown below in Tables 9, 10, and 11. 
Table 9: Posttraumatic Stress Disorder Checklist (PCL) Scores at 1, 4, and 8 months, Stein 
et al. Study 
 Gabapentin Propranolol Placebo 
PCL Score: 1 month 29 28 30 
PCL Score: 4 months 26 25 29 
PCL Score: 8 months 26 23 21 
 
Table 10: PTSD Rates at 4 Month Follow-Up, Stein et al. Study 
 Gabapentin Propranolol Placebo 
PTSD Rate 20% 25% 25% 
 
Table 11: Absolute Risk Reduction and Number Needed to Treat at 4 Month Follow-Up, 
Stein et al. Study 
CER EER ARR NNT 
25% 25% 0 0 
 
 
 Goulet, PTSD and Propranolol 
 
DISCUSSION 
 Propranolol is an often used, safe, widely available, inexpensive generic medication used 
in the treatment of hypertension, migraine prophylaxis, arrhythmias, and chest pain in the United 
States8. The three randomized, controlled, double-blind studies evaluated the efficacy of 
propranolol administration following a traumatic event in reducing the incidence of PTSD. 
While the cumulative results of the studies were inconclusive as to the effectiveness of 
propranolol in reducing PTSD incidence, the Nugent and Pitman studies demonstrated an 
observable, albeit small, benefit to using propranolol to reduce PTSD symptomology. In all three 
studies, small sample sizes limited both the significance of the findings as well as limiting 
generalizability. The Nugent et al study utilized 29 participants, while the Pitman and Stein 
studies utilized 45 and 48 participants, respectively. Another indisputable limitation of the 
studies is the inherent difficulty of recruiting acutely injured and traumatized patients to 
participate in a randomized study. Further studies are certainly warranted utilizing much larger 
sample sizes to truly determine the efficacy of propranolol in reducing the symptoms of PTSD.  
CONCLUSION 
 It is inconclusive at this time as to the benefit of using propranolol to decrease the 
symptoms and prevent the development of PTSD. However, the Nugent and Pitman studies 
support the clinical feasibility of this hypothesis. It can be said that the future study of this 
medication and its effect on the development of PTSD symptoms is certainly warranted; it is 
well documented that propranolol inhibits the actions of norepinephrine, a neurotransmitter that 
plays an integral role in the consolidation of emotionally charged memories, and the antagonism 
of this neurobiological mechanism is theorized to play a significant role in the evolution of this 
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disorder. Continued research should be undertaken with larger sample sizes in order to truly 
evaluate the efficacy of propranolol and its role in preventing PTSD.  
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